Preeclampsia and high serum levels of homocysteine;Preclampsia ed elevati livelli sierici di omocisteinemia

Minerva Ginecologica

Volumn 57, Issue 2, 2005, Pages 165-170

  Maruotti, G ^a   Del Bianco, A ^a,b   Amato, A N ^a   Lombardi, L ^a   Fulgeri, A M ^a   Pietropaolo, F ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; HEMATOCRIT; HUMAN; HYPERHOMOCYSTEINEMIA; PLACENTA; PREECLAMPSIA; PREGNANCY; PREGNANCY TOXEMIA; PRIMIGRAVIDA;

ADULT; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; PRE-ECLAMPSIA; PREGNANCY;

EID: 33745346764     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Pescetto G, De Cecco L, Pecorari D, Ragni N. Ginecologia ed Ostetricia. Ostetricia. Roma: Universo eds; 2001.
2. Sibai BM, Caritis SN, Thorn E, Klebanoff M, McNellis D, Rocco L et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute Of Child Health And Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993;329:1213-8.
3. Broughton Pipkin F, Roberts JM. Hypertension in pregnancy. J Hum Hypertens 2000;14:705-24.
4. eeman GG, Alexander JM, McIntire DD, Devaraj S, Laveno KJ. Homocysteine plasma concentration levels for the prediction of preeclampsia in women with cronic hypertension. AmJ Obstet Gynecol 2003;189:574-6.
5. Pijnenborg R, Luyten C, Vercruysse L, Van Assche FA. Attachment and differentiation in vitro of trophoblast from normal and preeclamptic human placentas. Am J Obstet Gynecol 1996;175:30-6.
6. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993;91:950-60.
7. Orange SJ, Painter D, Horvath J, Yu B, Trent R, Hennessey A. Placental endothelial nitric oxide synthase localization and expression in normal human pregnancy and pre-eclampsia. Clin Exp Pharmacol Physiol 2003;30:376-81.
8. Kadyrov M, Schmitz C, Black S, Kaufmann P, Huppertz B. Pre-eclampsia and maternal anaemia display reduced apoptosis and opposite invasive phenotypes of extravillous trophoblast. Placenta 2003;24:540-8.
9. Simmons LA, Hennessy A, Gillin AG, Jeremy RW. Uteroplacental blood flow and placental vascular endothelial growth factor in normotensive and pre-eclamptic pregnancy. BJOG 2000;107:678.
10. Hennessy A, Painter DM, Orange S, Horvath JS. Placental tissue interleukin-10 receptor distribution in pre-eclampsia. Am J Reprod Immunol 2003;49:377-81.
11. Powers RW, Evans RW, Majors AK, Ojimba JI, Ness RB, Crombleholme WR et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998;179:1605-11.
12. Flaut MM, Smith W, Kennedy K. Fetal fibronectin: the impact of a rapid test on the treatment of women with preterm labor symptoms. Am J Obestet Gynecol 2003;188:1588-93.
13. Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ 2002;325:301.
14. Closset E, Dufour P, Coeugnet C, Subtil D, Valat AS, Puech F. Value of fetal fibronectin research for predicting premature delivery. Gynecol Obstet Fertil 2001;29:808-13.
15. Paternoster DM, Stella A, Gerace P, Manganelli F, Plebani M, Snijders D et al. Biochemical markers for the prediction of spontaneous pre-term birth. Int J Gynaecol Obstet 2002;79:123-9.
16. Koenn ME. Fetal fibronectin. Clin Lab Sci 2002;15:96-8.
17. Jacobsson B, Mattsby-Baltzer I, Andersch B, Bokstrom H, Holst RM, Niholaitchouk N et al. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women in preterm labor. Acta Obstet Gynecol Scand 2003;82:423-31.
18. Lange M, Chen FK, Wessel J, Buscher U, Dudenhausen JW. Elevation of interleukin-6 levels in cervical secretions as a predictor of preterm delivery. Acta Obstet Gynecol Scand 2003;82:326-9.
19. Coleman MA, Keelan JA, McCowan LM, Townend KM, Mitchell MD. Predicting preterm delivery: comparison of cervicovaginal interleukin (IL)-1 beta, IL-6 and IL-8 with fetal fibronectin and cervical dilatation. Eur J Obstet Gynecol Reprod Biol 2001;95:154-8.
20. LaShay N, Gilson G, Joffe G, Quails C, Curet L. Will cervicovaginal interleukin-6 combined with fetal fibronectin testing improve the prediction of preterm delivery? J Matern Fetal Med 2000;9:336-41.
21. Bahar AM, Ghalib HW, Moosa RA, Zaki ZM, Thomas C, Nabri OA. Maternal serum interleukin-6, interleukin-8, TNFα and αINF in preterm labor. Acta Obstet Gynecol Scand 2003;82:543-9.
22. Dekker GA, deVries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs C et al. Underlying disorders associated woth severe early-onset preeclampsia Am J Obstet Gynecol 1995;173:1042-8.
23. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis. (Leiden Thrombophilia Study). Blood 1995;85:2756-6l.
24. Miletich J, Sherman L, Broze G. Abscence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987;317:991-6.
25. Cowchock S. The role of antiphospholipid antibodies in obstetric medicine. Curr Obstet Med 1991;10:905-8.
26. de Boer K, ten Cate JW, Sturk A, Borm JJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnanct. Am J Obstet Gynecol 1989;160:95-100.
27. Stamler JS, Osborne J, Jaraki O, Rabbani L, Mullins M, Singel D et al. Adverse vascular effects of homocysteine are modyulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
28. Rajkovic A, Catalane PM, Malinow MR. Elevated homocysteine levels with preeclampsia. Obstet Gynecol 1997;90:168-71.
29. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;342:619-22.
30. Roberts JM, Hubel CA. Oxidative stress ion preeclampsia. Am J Obstet Gynecol 2004;190:1177-8.
31. Roberts JM, Person GD, Culter JA, Lindheimer MD; National Healt Blood Institute. Summary of the NHLBI Working Group on Research on Hypertension during pregnancy. Hypertens Pregnancy 2003;22:109-27.
32. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
33. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
34. McCully KS. Homocysteinemia and ateriosclerosis. Am Heart J 1972;83:571-3.
35. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
36. Malinow MR, Kang SS, Taylor LM. Wong PW, Coull B, Inahara T et al. Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-8.
37. van den Berg M, Franken DG, Boers GH, Blom HJ, Jakobs C, Stehouwer CD et al. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and huperhocmocysteinemia. J Vasc Surg 1994;20:933-40.
38. Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr et al. Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathinione peroxidase. J Biol Chem 1997;272:17012-7.
39. Loscalzo J. The oxidant stress of hyperhomocysteinemia. Clin Invest 1996;98: 5-7, 1996.
40. Andersson A, Ultberg B, Brattstrom L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992;30:377-9.
41. Wouters MGAJ, Boers GHJ, Blom HJ. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993;60:820-5.
42. Goddjin-Wessel TAW, Wouters M, van de Molen EF, Spuijbroek MD, Steegers-Theunissen RP, Blom HJ et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996;66:23-9.
43. Fenton WA, Rosenberg LE. The metabolic basis of inherited diseases. Milano: McGraw Hill, 1964.
44. Rosenblatt DS. The metabolic bases of inherited diseases. Milano: Mc Graw Hill, 1989.
45. Finkelstein JD. Homocysteine. Int J Biochem Cell Biol 2000;32:385-9.
46. Finkelstein JD. Homocysteine: a history in progress. Nutr Rev 2000;58:193-204.
47. Malinow MR. Hyperhomocysteinemia. A common and easily reversible risk factor for occlusive atheroslcerosis. Circulation 1990;81:2004-6.
48. Boers GHJ. The clinical usefulness of hocysteine determinations. In: Smith U, Eriksson S, Lindgarde S. Genetic susceptibility to environmental factors- a challenge for public intervention. Stockholm: Almquist and Wiksell International; 1988.
49. Brattstrom L, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60.
50. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial injury and platelet response in its genesis. J Clin Invest 1976;58:731-41.
51. Hogg BB, Tamura T, Johnston KE, Dubard MB, Goldenberg RL. Second-trimester plasma homocysteine levels and pregnancy induced hypertension, preeclampsia, and intrauterine growth restriction. Am J Obstet Gynecol 2000;183:805-9.
52. Taylor RN, Crombleholme WR, Friedman SA, Jones LA, Casal DC, Roberts JM. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 1991;l65(4 Pt 1): 895-901.
53. Lorentzen B, Endersen MJ, Clause T, Henriksen T. Fasting serum free fatty acids and triglycerides are increase before 20 weeks of gestation in women who later develop preeclampsia. Hypertens Pregnancy 1994;12:157-60.